Influence of herbal extracts in physicochemical properties and stability of antibacterial gels

The use of plants to treat diseases and heal wounds is a custom that dates back thousands of years and is a legacy of ancient civilizations. Although a significant proportion of the planet's plant biodiversity is found on theAmerican continent, there are very few pharmaceutical products developed from it. This work aimed to develop and characterize topical formulations (gels and emulgels), including a combination of plant extracts with recognized antibacterial activity. Hydroalcoholic extracts of Lippia turbinata Griseb. and Lippia alba (Mill.) N. E. Brown were obtained by leaching. The excipients used were Carbopol® 934 and 940, Sepigel® 305, sodium carboxymethylcellulose, methylcellulose, propylene glycol, and ethanol. The finished product was characterized by properties: organoleptic characteristics, extensibility, pH, texture profile, permeation performance, and microbiological quality. Then, they were subjected to stability studies in different conditions of temperature and humidity. They had a characteristic smell of plant species, color brown, without the presence of lumps, and with good extensibility. The gels had an in vitro permeation of porcine skin of up to 30% and low retention in the epithelium (<15%). They did not present microbial contamination and were stable for six months. Of the gels formulated, the gel with Sepigel® 4% (w/w) presented a better appearance. These results demonstrate the feasibility of transporting non-hydro soluble extracts in a gel formulation. All formulations are appropriate to preserve the antibacterial effect of original extracts. They maintain stability over time without the use of antimicrobial preservatives.Fil: Pérez Zamora, Cristina Marisel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Chaco Austral. Departamento de Ciencias Básicas y Aplicadas; ArgentinaFil: Michaluk, Ariel Germán. Universidad Nacional del Chaco Austral; ArgentinaFil: Torres, Carola Analía. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Nordeste. Instituto de Investigaciones En Procesos Tecnologicos Avanzados. - Universidad Nacional del Chaco Austral. Instituto de Investigaciones En Procesos Tecnologicos Avanzados.; ArgentinaFil: Mouriño, Viviana Silvia Lourdes. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Chiappetta, Diego Andrés. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Nuñez, María Beatriz. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Nordeste. Instituto de Investigaciones En Procesos Tecnologicos Avanzados. - Universidad Nacional del Chaco Austral. Instituto de Investigaciones En Procesos Tecnologicos Avanzados.; Argentina. Universidad Nacional del Chaco Austral. Departamento de Ciencias Básicas y Aplicadas; Argentin

Taste masking of paracetamol using microencapsulation

Este estudio muestra cómo enmascarar el sabor desagradable del paracetamol (PCT) utilizado por vía oral sin interferir con la apropiada velocidad de liberación de la droga. Micropartículas conteniendo PCT fueron obtenidas por una técnica de emulsificación/gelificación interna, la cual permite obtener un sistema con óptimas características micromeríticas y de porcentaje de entrampamiento. Se evaluó la liberación de PCT desde las micropartículas versus cápsulas. Las micropartículas preparadas fueron sometidas a una prueba de sabor en un panel de 20 voluntarios. El sabor desagradable del PCT fue significativamente enmascarado por microencapsulación.This study assesses how to mask the unpleasant taste of paracetamol (PCT) when is used orally without interfering with an appropriate rate of drug release. Microparticles containing PCT were formed by emulsification/internal gelation, a technique that allowed to obtain a system with ideal micromeritic characteristics and major drug loading. PCT release from microparticles was evaluated versus gelatin capsules. Sensory tests were carried out in 20 volunteers. The unpleasant taste of PCT was significantly masked by microencapsulation.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Taste masking of paracetamol using microencapsulation

Este estudio muestra cómo enmascarar el sabor desagradable del paracetamol (PCT) utilizado por vía oral sin interferir con la apropiada velocidad de liberación de la droga. Micropartículas conteniendo PCT fueron obtenidas por una técnica de emulsificación/gelificación interna, la cual permite obtener un sistema con óptimas características micromeríticas y de porcentaje de entrampamiento. Se evaluó la liberación de PCT desde las micropartículas versus cápsulas. Las micropartículas preparadas fueron sometidas a una prueba de sabor en un panel de 20 voluntarios. El sabor desagradable del PCT fue significativamente enmascarado por microencapsulación.This study assesses how to mask the unpleasant taste of paracetamol (PCT) when is used orally without interfering with an appropriate rate of drug release. Microparticles containing PCT were formed by emulsification/internal gelation, a technique that allowed to obtain a system with ideal micromeritic characteristics and major drug loading. PCT release from microparticles was evaluated versus gelatin capsules. Sensory tests were carried out in 20 volunteers. The unpleasant taste of PCT was significantly masked by microencapsulation.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the replication fork-protection factor Timeless promotes sister chromatid cohesion.

Establishment of sister chromatid cohesion is coupled to DNA replication, but the underlying molecular mechanisms are incompletely understood. DDX11 (also named ChlR1) is a super-family 2 Fe-S cluster-containing DNA helicase implicated in Warsaw breakage syndrome (WABS). Herein, we examined the role of DDX11 in cohesion establishment in human cells. We demonstrated that DDX11 interacts with Timeless, a component of the replication fork-protection complex, through a conserved peptide motif. The DDX11-Timeless interaction is critical for sister chromatid cohesion in interphase and mitosis. Immunofluorescence studies further revealed that cohesin association with chromatin requires DDX11. Finally, we demonstrated that DDX11 localises at nascent DNA by SIRF analysis. Moreover, we found that DDX11 promotes cohesin binding to the DNA replication forks in concert with Timeless and that recombinant purified cohesin interacts with DDX11 in vitro. Collectively, our results establish a critical role for the DDX11-Timeless interaction in coordinating DNA replication with sister chromatid cohesion, and have important implications for understanding the molecular basis of WABS

Sistemas dispersos II: formulación de suspensiones, emulsiones. Formas farmacéuticas orales

Este manual aborda los temas prioritarios en el campo de la tecnología farmacéutica y los avances fundamentales que hubo en los últimos años a raíz de los estudios realizados en cada una de las formas farmacéuticas en todas las etapas de la producción de medicamentos. La progresiva introducción de los atributos de eficacia, seguridad y confiabilidad en su diseño y producción que se suman a los ya clásicos de identidad, pureza, potencia y estabilidad ha enriquecido la tecnología farmacéutica con la incorporación de metodologías y conocimientos que permiten satisfacer los nuevos requerimientos. Por ello, esta publicación pone especial énfasis en dar una visión tanto de la situación actual como de la perspectiva hacia el futuro cercano en cada tema, de manera que el lector pueda adquirir un panorama de la evolución de cada uno de los tópicos.Fil: Mouriño, Viviana Silvia Lourdes. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Bernabeu, Ezequiel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Moretton, Marcela Analía. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Dobrecky, Cecilia Beatriz. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Buontempo, Fabian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Chiappetta, Diego Andrés. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Lucangioli, Silvia Edith. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentin

Discard or not discard, that is the question: an international survey across 117 embryologists on the clinical management of borderline quality blastocysts

Study question: Do embryologists from different European countries agree on embryo disposition decisions ('use' or 'discard') about Day 7 (>144 h post-insemination) and/or low-quality blastocysts (LQB

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study

Background Risk of relapse or progression remains high in the treatment of most patients with epithelial ovarian cancer, and development of a molecular predictor could be a valuable tool for stratification of patients by risk. We aimed to develop a microRNA (miRNA)-based molecular classifier that can predict risk of progression or relapse in patients with epithelial ovarian cancer. Methods We analysed miRNA expression profiles in three cohorts of samples collected at diagnosis. We used 179 samples from a Multicenter Italian Trial in Ovarian cancer trial (cohort OC179) to develop the model and 263 samples from two cancer centres (cohort OC263) and 452 samples from The Cancer Genome Atlas epithelial ovarian cancer series (cohort OC452) to validate the model. The primary clinical endpoint was progression-free survival, and we adapted a semi-supervised prediction method to the miRNA expression profile of OC179 to identify miRNAs that predict risk of progression. We assessed the independent prognostic role of the model using multivariable analysis with a Cox regression model. Findings We identified 35 miRNAs that predicted risk of progression or relapse and used them to create a prognostic model, the 35-miRNA-based predictor of Risk of Ovarian Cancer Relapse or progression (MiROvaR). MiROvaR was able to classify patients in OC179 into a high-risk group (89 patients; median progression-free survival 18 months [95% CI 15\u201322]) and a low-risk group (90 patients; median progression-free survival 38 months [24\u2013not estimable]; hazard ratio [HR] 1\ub785 [1\ub729\u20132\ub764], p=0\ub700082). MiROvaR was a significant predictor of progression in the two validation sets (OC263 HR 3\ub716, 95% CI 2\ub733\u20134\ub729, p&lt;0\ub70001; OC452 HR 1\ub739, 95% CI 1\ub711\u20131\ub774, p=0\ub70047) and maintained its independent prognostic effect when adjusted for relevant clinical covariates using multivariable analyses (OC179: adjusted HR 1\ub748, 95% CI 1\ub703\u20132\ub713, p=0\ub7036; OC263: adjusted HR 3\ub709 [2\ub724\u20134\ub728], p&lt;0\ub70001; and OC452: HR 1\ub741 [1\ub711\u20131\ub779], p=0\ub70047). Interpretation MiROvaR is a potential predictor of epithelial ovarian cancer progression and has prognostic value independent of relevant clinical covariates. MiROvaR warrants further investigation for the development of a clinical-grade prognostic assay. Funding AIRC and CARIPLO Foundation